PTC fails phase 3, and looks to a regulatory filing
Vatiquinone’s pivotal failure in Friedreich’s ataxia prompts a data dredge to come up with a regulatory package. And why not?
Tecentriq runs out of luck in triple-negative breast cancer
Roche puts on a brave face as its anti-PD-L1 drug fails yet another TNBC study, this time in the adjuvant setting.
